

Diabetes Drugs Market By Drug Class (Insulin, GLP-1 Receptor Agonists, DPP-4 Inhibitors, SGLT2 Inhibitors, Others) , By Diabetes Type (Type 1, Type 2) By Route of Administration (Oral, Subcutaneous, Intravenous) By Distribution Channel (Online pharmacies, Hospital Pharmacies, Retail Pharmacies) : Global Opportunity Analysis and Industry Forecast, 2024-2033

<https://marketpublishers.com/r/DAC0ED009B2CEN.html>

Date: September 2024

Pages: 280

Price: US\$ 2,655.00 (Single User License)

ID: DAC0ED009B2CEN

Abstracts

The diabetes drugs market was valued at \$79.3 billion in 2023, and is projected to reach \$157.9 billion by 2033, growing at a CAGR of 7.1% from 2024 to 2033.

Diabetes drugs are pharmaceutical treatments designed to help manage blood sugar levels in individuals diagnosed with diabetes. These medications work by improving insulin function, increasing insulin production, or reducing the amount of glucose released by the liver. Continuous advancements in diabetes medications aim to improve patient outcomes and reduce long-term complications associated with poor blood sugar control.

The growth of the global diabetes drugs market is driven by alarming rise in prevalence of diabetes triggered due to factors such as obesity, sedentary lifestyles, and aging population. According to a study published by the International Diabetes Federation, approximately 537 million adults are currently living with diabetes. This number is estimated to increase to 643 million by 2030 and 783 million by 2045. In addition, increase in government support for diabetes management programs, awareness campaigns, and funding for research and development fosters the market growth.

Moreover, surge in geriatric population notably contributes toward the growth of the global market. This is attributed to the fact that as people age, their bodies may become less sensitive to insulin, leading to insulin resistance. This condition makes it harder for the body to use insulin effectively, which can result in higher blood sugar levels. As per the World Health Organization, the number of people aged 60 years and older was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050. Furthermore, increase in awareness of lifestyle modifications and their impact on diabetes management can drive demand for supportive medications that assist patients in maintaining optimal glucose levels. However, high price of diabetes medications, especially newer and innovative therapies, restrains the growth of the global market. In addition, side effects and adverse reactions associated with some diabetes drugs such as gastrointestinal issues, weight gain, or increased risk of hypoglycemia hamper the market growth. On the contrary, innovations such as smart insulin delivery systems, continuous glucose monitoring devices, and telemedicine solutions enhance the management of diabetes and drive demand for related medications. Such developments are expected to offer lucrative opportunities for the expansion of the global market during the forecast period.

The global diabetes drugs industry is segmented into drug class, diabetes type, route of administration, distribution channel, and region. By drug class, the market is classified into insulin, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, and others. On the basis of diabetes type, it is divided into type 1 and type 2. Depending on route of administration, it is segregated into oral, subcutaneous, and intravenous. As per distribution channel, it is segregated into online pharmacies, hospital pharmacies, and retail pharmacies. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By drug class, the GLP-1 receptor agonists segment dominated the market share in 2023.

On the basis of diabetes type, the type 2 segment garnered the largest share in 2023.

Depending on route of administration, the subcutaneous segment was the major shareholder 2023.

As per distribution channel, the retail pharmacies segment led the market share in 2023.

Region wise, North America held a dominant position in the market in 2023.

Competition Analysis

Competitive analysis and profiles of the major players in the global diabetes drugs market include Novo Nordisk A/S, Sanofi, Merck & Co., Inc., Eli Lilly and Company., AstraZeneca, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Novartis AG, Johnson & Johnson, and Bayer AG. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market .

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)

5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

Free Upcoming Version on the Purchase of Five and Enterprise User License.

16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

Free data Pack on the Five and Enterprise User License. (Excel version of the report)

Free Updated report if the report is 6-12 months old or older.

24-hour priority response*

Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines

Additional company profiles with specific to client's interest

Additional country or region analysis- market size and forecast

Expanded list for Company Profiles

Historic market data

Key Market Segments

By Drug Class

Insulin

GLP-1 Receptor Agonists

DPP-4 Inhibitors

SGLT2 Inhibitors

Others

By Diabetes Type

Type 1

Type 2

By Route Of Administration

Oral

Subcutaneous

Intravenous

By Distribution Channel

Online pharmacies

Hospital Pharmacies

Retail Pharmacies

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Rest of Europe

Asia-Pacific

Japan

China

Australia

India

South Korea

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

Key Market Players

Novo Nordisk A/S

Sanofi

Merck & Co., Inc.

Eli Lilly and Company.

AstraZeneca

Takeda Pharmaceutical Company Limited

Boehringer Ingelheim International GmbH

Novartis AG

Johnson & Johnson

Bayer AG

Contents

CHAPTER 1: INTRODUCTION

- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
 - 1.4.1. Primary Research
 - 1.4.2. Secondary Research
 - 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

- 3.1. Market Definition and Scope
- 3.2. Key Findings
 - 3.2.1. Top Investment Pockets
 - 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
 - 3.3.1. Bargaining Power of Suppliers
 - 3.3.2. Threat of New Entrants
 - 3.3.3. Threat of Substitutes
 - 3.3.4. Competitive Rivalry
 - 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
 - 3.4.1. Drivers
 - 3.4.2. Restraints
 - 3.4.3. Opportunities

CHAPTER 4: DIABETES DRUGS MARKET, BY DRUG CLASS

- 4.1. Market Overview
 - 4.1.1 Market Size and Forecast, By Drug Class
- 4.2. Insulin
 - 4.2.1. Key Market Trends, Growth Factors and Opportunities

- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. GLP-1 Receptor Agonists
 - 4.3.1. Key Market Trends, Growth Factors and Opportunities
 - 4.3.2. Market Size and Forecast, By Region
 - 4.3.3. Market Share Analysis, By Country
- 4.4. DPP-4 Inhibitors
 - 4.4.1. Key Market Trends, Growth Factors and Opportunities
 - 4.4.2. Market Size and Forecast, By Region
 - 4.4.3. Market Share Analysis, By Country
- 4.5. SGLT2 Inhibitors
 - 4.5.1. Key Market Trends, Growth Factors and Opportunities
 - 4.5.2. Market Size and Forecast, By Region
 - 4.5.3. Market Share Analysis, By Country
- 4.6. Others
 - 4.6.1. Key Market Trends, Growth Factors and Opportunities
 - 4.6.2. Market Size and Forecast, By Region
 - 4.6.3. Market Share Analysis, By Country

CHAPTER 5: DIABETES DRUGS MARKET, BY DIABETES TYPE

- 5.1. Market Overview
 - 5.1.1 Market Size and Forecast, By Diabetes Type
- 5.2. Type
 - 5.2.1. Key Market Trends, Growth Factors and Opportunities
 - 5.2.2. Market Size and Forecast, By Region
 - 5.2.3. Market Share Analysis, By Country
- 5.3. Type
 - 5.3.1. Key Market Trends, Growth Factors and Opportunities
 - 5.3.2. Market Size and Forecast, By Region
 - 5.3.3. Market Share Analysis, By Country

CHAPTER 6: DIABETES DRUGS MARKET, BY ROUTE OF ADMINISTRATION

- 6.1. Market Overview
 - 6.1.1 Market Size and Forecast, By Route Of Administration
- 6.2. Oral
 - 6.2.1. Key Market Trends, Growth Factors and Opportunities
 - 6.2.2. Market Size and Forecast, By Region

- 6.2.3. Market Share Analysis, By Country
- 6.3. Subcutaneous
 - 6.3.1. Key Market Trends, Growth Factors and Opportunities
 - 6.3.2. Market Size and Forecast, By Region
 - 6.3.3. Market Share Analysis, By Country
- 6.4. Intravenous
 - 6.4.1. Key Market Trends, Growth Factors and Opportunities
 - 6.4.2. Market Size and Forecast, By Region
 - 6.4.3. Market Share Analysis, By Country

CHAPTER 7: DIABETES DRUGS MARKET, BY DISTRIBUTION CHANNEL

- 7.1. Market Overview
 - 7.1.1 Market Size and Forecast, By Distribution Channel
- 7.2. Online Pharmacies
 - 7.2.1. Key Market Trends, Growth Factors and Opportunities
 - 7.2.2. Market Size and Forecast, By Region
 - 7.2.3. Market Share Analysis, By Country
- 7.3. Hospital Pharmacies
 - 7.3.1. Key Market Trends, Growth Factors and Opportunities
 - 7.3.2. Market Size and Forecast, By Region
 - 7.3.3. Market Share Analysis, By Country
- 7.4. Retail Pharmacies
 - 7.4.1. Key Market Trends, Growth Factors and Opportunities
 - 7.4.2. Market Size and Forecast, By Region
 - 7.4.3. Market Share Analysis, By Country

CHAPTER 8: DIABETES DRUGS MARKET, BY REGION

- 8.1. Market Overview
 - 8.1.1 Market Size and Forecast, By Region
- 8.2. North America
 - 8.2.1. Key Market Trends and Opportunities
 - 8.2.2. Market Size and Forecast, By Drug Class
 - 8.2.3. Market Size and Forecast, By Diabetes Type
 - 8.2.4. Market Size and Forecast, By Route Of Administration
 - 8.2.5. Market Size and Forecast, By Distribution Channel
 - 8.2.6. Market Size and Forecast, By Country
 - 8.2.7. U.S. Diabetes Drugs Market

- 8.2.7.1. Market Size and Forecast, By Drug Class
- 8.2.7.2. Market Size and Forecast, By Diabetes Type
- 8.2.7.3. Market Size and Forecast, By Route Of Administration
- 8.2.7.4. Market Size and Forecast, By Distribution Channel
- 8.2.8. Canada Diabetes Drugs Market
 - 8.2.8.1. Market Size and Forecast, By Drug Class
 - 8.2.8.2. Market Size and Forecast, By Diabetes Type
 - 8.2.8.3. Market Size and Forecast, By Route Of Administration
 - 8.2.8.4. Market Size and Forecast, By Distribution Channel
- 8.2.9. Mexico Diabetes Drugs Market
 - 8.2.9.1. Market Size and Forecast, By Drug Class
 - 8.2.9.2. Market Size and Forecast, By Diabetes Type
 - 8.2.9.3. Market Size and Forecast, By Route Of Administration
 - 8.2.9.4. Market Size and Forecast, By Distribution Channel
- 8.3. Europe
 - 8.3.1. Key Market Trends and Opportunities
 - 8.3.2. Market Size and Forecast, By Drug Class
 - 8.3.3. Market Size and Forecast, By Diabetes Type
 - 8.3.4. Market Size and Forecast, By Route Of Administration
 - 8.3.5. Market Size and Forecast, By Distribution Channel
 - 8.3.6. Market Size and Forecast, By Country
 - 8.3.7. Germany Diabetes Drugs Market
 - 8.3.7.1. Market Size and Forecast, By Drug Class
 - 8.3.7.2. Market Size and Forecast, By Diabetes Type
 - 8.3.7.3. Market Size and Forecast, By Route Of Administration
 - 8.3.7.4. Market Size and Forecast, By Distribution Channel
 - 8.3.8. France Diabetes Drugs Market
 - 8.3.8.1. Market Size and Forecast, By Drug Class
 - 8.3.8.2. Market Size and Forecast, By Diabetes Type
 - 8.3.8.3. Market Size and Forecast, By Route Of Administration
 - 8.3.8.4. Market Size and Forecast, By Distribution Channel
 - 8.3.9. UK Diabetes Drugs Market
 - 8.3.9.1. Market Size and Forecast, By Drug Class
 - 8.3.9.2. Market Size and Forecast, By Diabetes Type
 - 8.3.9.3. Market Size and Forecast, By Route Of Administration
 - 8.3.9.4. Market Size and Forecast, By Distribution Channel
 - 8.3.10. Italy Diabetes Drugs Market
 - 8.3.10.1. Market Size and Forecast, By Drug Class
 - 8.3.10.2. Market Size and Forecast, By Diabetes Type

- 8.3.10.3. Market Size and Forecast, By Route Of Administration
- 8.3.10.4. Market Size and Forecast, By Distribution Channel
- 8.3.11. Spain Diabetes Drugs Market
 - 8.3.11.1. Market Size and Forecast, By Drug Class
 - 8.3.11.2. Market Size and Forecast, By Diabetes Type
 - 8.3.11.3. Market Size and Forecast, By Route Of Administration
 - 8.3.11.4. Market Size and Forecast, By Distribution Channel
- 8.3.12. Rest Of Europe Diabetes Drugs Market
 - 8.3.12.1. Market Size and Forecast, By Drug Class
 - 8.3.12.2. Market Size and Forecast, By Diabetes Type
 - 8.3.12.3. Market Size and Forecast, By Route Of Administration
 - 8.3.12.4. Market Size and Forecast, By Distribution Channel
- 8.4. Asia-Pacific
 - 8.4.1. Key Market Trends and Opportunities
 - 8.4.2. Market Size and Forecast, By Drug Class
 - 8.4.3. Market Size and Forecast, By Diabetes Type
 - 8.4.4. Market Size and Forecast, By Route Of Administration
 - 8.4.5. Market Size and Forecast, By Distribution Channel
 - 8.4.6. Market Size and Forecast, By Country
 - 8.4.7. Japan Diabetes Drugs Market
 - 8.4.7.1. Market Size and Forecast, By Drug Class
 - 8.4.7.2. Market Size and Forecast, By Diabetes Type
 - 8.4.7.3. Market Size and Forecast, By Route Of Administration
 - 8.4.7.4. Market Size and Forecast, By Distribution Channel
 - 8.4.8. China Diabetes Drugs Market
 - 8.4.8.1. Market Size and Forecast, By Drug Class
 - 8.4.8.2. Market Size and Forecast, By Diabetes Type
 - 8.4.8.3. Market Size and Forecast, By Route Of Administration
 - 8.4.8.4. Market Size and Forecast, By Distribution Channel
 - 8.4.9. Australia Diabetes Drugs Market
 - 8.4.9.1. Market Size and Forecast, By Drug Class
 - 8.4.9.2. Market Size and Forecast, By Diabetes Type
 - 8.4.9.3. Market Size and Forecast, By Route Of Administration
 - 8.4.9.4. Market Size and Forecast, By Distribution Channel
 - 8.4.10. India Diabetes Drugs Market
 - 8.4.10.1. Market Size and Forecast, By Drug Class
 - 8.4.10.2. Market Size and Forecast, By Diabetes Type
 - 8.4.10.3. Market Size and Forecast, By Route Of Administration
 - 8.4.10.4. Market Size and Forecast, By Distribution Channel

8.4.11. South Korea Diabetes Drugs Market

8.4.11.1. Market Size and Forecast, By Drug Class

8.4.11.2. Market Size and Forecast, By Diabetes Type

8.4.11.3. Market Size and Forecast, By Route Of Administration

8.4.11.4. Market Size and Forecast, By Distribution Channel

8.4.12. Rest of Asia-Pacific Diabetes Drugs Market

8.4.12.1. Market Size and Forecast, By Drug Class

8.4.12.2. Market Size and Forecast, By Diabetes Type

8.4.12.3. Market Size and Forecast, By Route Of Administration

8.4.12.4. Market Size and Forecast, By Distribution Channel

8.5. LAMEA

8.5.1. Key Market Trends and Opportunities

8.5.2. Market Size and Forecast, By Drug Class

8.5.3. Market Size and Forecast, By Diabetes Type

8.5.4. Market Size and Forecast, By Route Of Administration

8.5.5. Market Size and Forecast, By Distribution Channel

8.5.6. Market Size and Forecast, By Country

8.5.7. Brazil Diabetes Drugs Market

8.5.7.1. Market Size and Forecast, By Drug Class

8.5.7.2. Market Size and Forecast, By Diabetes Type

8.5.7.3. Market Size and Forecast, By Route Of Administration

8.5.7.4. Market Size and Forecast, By Distribution Channel

8.5.8. Saudi Arabia Diabetes Drugs Market

8.5.8.1. Market Size and Forecast, By Drug Class

8.5.8.2. Market Size and Forecast, By Diabetes Type

8.5.8.3. Market Size and Forecast, By Route Of Administration

8.5.8.4. Market Size and Forecast, By Distribution Channel

8.5.9. South Africa Diabetes Drugs Market

8.5.9.1. Market Size and Forecast, By Drug Class

8.5.9.2. Market Size and Forecast, By Diabetes Type

8.5.9.3. Market Size and Forecast, By Route Of Administration

8.5.9.4. Market Size and Forecast, By Distribution Channel

8.5.10. Rest of LAMEA Diabetes Drugs Market

8.5.10.1. Market Size and Forecast, By Drug Class

8.5.10.2. Market Size and Forecast, By Diabetes Type

8.5.10.3. Market Size and Forecast, By Route Of Administration

8.5.10.4. Market Size and Forecast, By Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

- 9.1. Introduction
- 9.2. Top Winning Strategies
- 9.3. Product Mapping Of Top 10 Player
- 9.4. Competitive Dashboard
- 9.5. Competitive Heatmap
- 9.6. Top Player Positioning, 2023

CHAPTER 10: COMPANY PROFILES

- 10.1. Novo Nordisk A/S
 - 10.1.1. Company Overview
 - 10.1.2. Key Executives
 - 10.1.3. Company Snapshot
 - 10.1.4. Operating Business Segments
 - 10.1.5. Product Portfolio
 - 10.1.6. Business Performance
 - 10.1.7. Key Strategic Moves and Developments
- 10.2. Sanofi
 - 10.2.1. Company Overview
 - 10.2.2. Key Executives
 - 10.2.3. Company Snapshot
 - 10.2.4. Operating Business Segments
 - 10.2.5. Product Portfolio
 - 10.2.6. Business Performance
 - 10.2.7. Key Strategic Moves and Developments
- 10.3. Merck And Co., Inc.
 - 10.3.1. Company Overview
 - 10.3.2. Key Executives
 - 10.3.3. Company Snapshot
 - 10.3.4. Operating Business Segments
 - 10.3.5. Product Portfolio
 - 10.3.6. Business Performance
 - 10.3.7. Key Strategic Moves and Developments
- 10.4. Eli Lilly And Company.
 - 10.4.1. Company Overview
 - 10.4.2. Key Executives
 - 10.4.3. Company Snapshot
 - 10.4.4. Operating Business Segments

- 10.4.5. Product Portfolio
- 10.4.6. Business Performance
- 10.4.7. Key Strategic Moves and Developments
- 10.5. AstraZeneca
 - 10.5.1. Company Overview
 - 10.5.2. Key Executives
 - 10.5.3. Company Snapshot
 - 10.5.4. Operating Business Segments
 - 10.5.5. Product Portfolio
 - 10.5.6. Business Performance
 - 10.5.7. Key Strategic Moves and Developments
- 10.6. Takeda Pharmaceutical Company Limited
 - 10.6.1. Company Overview
 - 10.6.2. Key Executives
 - 10.6.3. Company Snapshot
 - 10.6.4. Operating Business Segments
 - 10.6.5. Product Portfolio
 - 10.6.6. Business Performance
 - 10.6.7. Key Strategic Moves and Developments
- 10.7. Boehringer Ingelheim International GmbH
 - 10.7.1. Company Overview
 - 10.7.2. Key Executives
 - 10.7.3. Company Snapshot
 - 10.7.4. Operating Business Segments
 - 10.7.5. Product Portfolio
 - 10.7.6. Business Performance
 - 10.7.7. Key Strategic Moves and Developments
- 10.8. Novartis AG
 - 10.8.1. Company Overview
 - 10.8.2. Key Executives
 - 10.8.3. Company Snapshot
 - 10.8.4. Operating Business Segments
 - 10.8.5. Product Portfolio
 - 10.8.6. Business Performance
 - 10.8.7. Key Strategic Moves and Developments
- 10.9. Johnson And Johnson
 - 10.9.1. Company Overview
 - 10.9.2. Key Executives
 - 10.9.3. Company Snapshot

- 10.9.4. Operating Business Segments
- 10.9.5. Product Portfolio
- 10.9.6. Business Performance
- 10.9.7. Key Strategic Moves and Developments
- 10.10. Bayer AG
 - 10.10.1. Company Overview
 - 10.10.2. Key Executives
 - 10.10.3. Company Snapshot
 - 10.10.4. Operating Business Segments
 - 10.10.5. Product Portfolio
 - 10.10.6. Business Performance
 - 10.10.7. Key Strategic Moves and Developments

I would like to order

Product name: Diabetes Drugs Market By Drug Class (Insulin, GLP-1 Receptor Agonists, DPP-4 Inhibitors, SGLT2 Inhibitors, Others) , By Diabetes Type (Type 1, Type 2) By Route of Administration (Oral, Subcutaneous, Intravenous) By Distribution Channel (Online pharmacies, Hospital Pharmacies, Retail Pharmacies) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Product link: <https://marketpublishers.com/r/DAC0ED009B2CEN.html>

Price: US\$ 2,655.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DAC0ED009B2CEN.html>